Search
Biospace news
RSS Feed for Biotech, Pharmaceutical and Clinical Research News | BioSpace (Generated by New Sloth)
Updated: 8 hours 34 min ago
Takeda Cuts Jobs in California Following Massachusetts Layoffs (Updated)
Takeda Cuts Jobs in California Following Massachusetts Layoffs (Updated) 5/24/2023
FDA Approves First Nasal Nalmefene Spray for Opioid Overdose
FDA Approves First Nasal Nalmefene Spray for Opioid Overdose 5/23/2023
Roche Terminates Second Phase II Schizophrenia Trial
Roche Terminates Second Phase II Schizophrenia Trial 5/23/2023
ReNAgade Launches with $300M to More Easily Deliver RNA Medicines
ReNAgade Launches with $300M to More Easily Deliver RNA Medicines 5/23/2023
Ironwood to Pay $1B to Acquire VectivBio, Late-Stage Digestive Therapy
Ironwood to Pay $1B to Acquire VectivBio, Late-Stage Digestive Therapy 5/23/2023
Billy Dunn’s Prothena Board Position Reignites Ethical Debate
Billy Dunn’s Prothena Board Position Reignites Ethical Debate 5/23/2023
Blueprint Adds Indolent Systemic Mastocytosis to Ayvakit’s Label
Blueprint Adds Indolent Systemic Mastocytosis to Ayvakit’s Label 5/23/2023
10 Pharma Tech Jobs Available Now
10 Pharma Tech Jobs Available Now 5/23/2023
AbbVie, Genmab Score FDA Nod for DLBCL as Blood Cancer Space Heats Up
AbbVie, Genmab Score FDA Nod for DLBCL as Blood Cancer Space Heats Up 5/22/2023
Phase III Results Prime Dupixent as First Potential Biologic Approval for COPD
Phase III Results Prime Dupixent as First Potential Biologic Approval for COPD 5/22/2023
Phase III Results Prime Dupixent as First Potential Biologic Approval for COPD
Phase III Results Prime Dupixent as First Potential Biologic Approval for COPD 5/22/2023
Krystal Gets First FDA Approval for Redosable Gene Therapy, Rare Skin Disease
Krystal Gets First FDA Approval for Redosable Gene Therapy, Rare Skin Disease 5/22/2023
Krystal Gets First FDA Approval for Redosable Gene Therapy, Rare Skin Disease
Krystal Gets First FDA Approval for Redosable Gene Therapy, Rare Skin Disease 5/22/2023
Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat
Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat 5/22/2023
Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat
Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat 5/22/2023
Biopharma Targets the Untapped Potential of the Human Healthspan
Biopharma Targets the Untapped Potential of the Human Healthspan 5/22/2023
Opinion: Sarepta Enters Uncharted Territory with Adcomm Approval
Opinion: Sarepta Enters Uncharted Territory with Adcomm Approval 5/22/2023
FDA Action Alert: Blueprint, Opiant and Lexicon
FDA Action Alert: Blueprint, Opiant and Lexicon 5/22/2023
ReCode–a New Contestant in the mRNA Race
ReCode–a New Contestant in the mRNA Race 5/22/2023
Intercept’s NASH Treatment Fails to Win Support of FDA Advisory Committee
Intercept’s NASH Treatment Fails to Win Support of FDA Advisory Committee 5/20/2023
World Pharma News
- Bayer launches unit to develop new precision health consumer products
- Researchers use ‘natural’ system to identify proteins most useful for developing an effective HIV vaccine
- New blood biomarker can predict if cognitively healthy elderly will develop Alzheimer's disease
- Large study provides scientists with deeper insight into long COVID symptoms
- Pfizer's PAXLOVID™ receives FDA approval for adult patients at high risk of progression to severe COVID-19